Board of Governors of the Federal Reserve System, December 4, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–32747 Filed 12–9–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Draft Guidelines for HIV Case Surveillance, Including Monitoring HIV Infection and Acquired Immunodeficiency Syndrome (AIDS)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice and Request for Comments.

SUMMARY: This notice announces the availability for public comment of a document entitled ''Draft Guidelines for HIV Case Surveillance, Including Monitoring HIV Infection and Acquired Immunodeficiency Syndrome (AIDS)''.

DATES: Comments must be submitted in writing on or before January 11, 1999. Comments should be submitted to the Technical Information and Communications Branch, Mailstop E–49, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia 30333; Fax: 404–639–2007; E-mail: hivmail@cdc.gov.

FOR FURTHER INFORMATION CONTACT: Requests for copies of the Draft HIV Case Surveillance Guidelines should be submitted to the CDC National Prevention Information Network, P.O. Box 6003, Rockville, Maryland 20849–6003; telephone (800) 458–5231; or copies can be obtained from the CDC website at http://www.cdc.gov/nchstp/hiv__aids/dhap.htm.

SUPPLEMENTARY INFORMATION: From 1995 to 1996, the incidence of both deaths and opportunistic infections (OIs) due to AIDS declined in the United States for the first time in the history of the epidemic (6 percent for OIs; 23 percent for deaths) as reported in the September 19, 1997, Morbidity and Mortality Weekly Report (MMWR) (Volume 46, pp. 861–867). These declines reflect recent advances in treatment of HIV infection and the provision of care and services that have slowed the progression of AIDS for HIV-infected persons on therapy and the success of HIV prevention and education efforts that have encouraged early diagnosis and have helped to reduce the number of Americans becoming infected with HIV.

In response to these changes in HIV treatment practices and new information needs of public health programs, CDC, the Council of State and Territorial Epidemiologists (CSTE), and most other public health and AIDS organizations have recommended that all States and territories conduct HIV case surveillance in addition to AIDS surveillance. In this manner, the AIDS/HIV epidemic can be tracked more accurately, and appropriate information about HIV/AIDS can be made available to policymakers. As of July 1998, a total of 32 States were conducting HIV case surveillance using the same methods as surveillance for AIDS. Because some States (many with large numbers of AIDS cases) do not report HIV case numbers, interpretations of available HIV data are difficult. To gain more reliable information about the prevalence, incidence, and future directions of HIV infection and the impact on specific populations such as racial and ethnic minorities and women, CDC is proposing that the current surveillance system be expanded to include HIV case reporting for all States and is publishing guidelines that States can use to implement HIV surveillance.

Dated: December 3, 1998.

Jeffrey P. Koplan,

Director, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–32617 Filed 12–9–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 78G–0133]

Procter & Gamble Co.; Withdrawal of GRAS Affirmation Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a petition (GRASP MF–3710) proposing affirmation that cellulose fines used as a feedstuff for livestock are generally recognized as safe (GRAS).

FOR FURTHER INFORMATION CONTACT: Sharon A. Benz, Center for Veterinary Medicine (HFV–228), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6657.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of May 19, 1978 (43 FR 21727), FDA announced that a petition (GRASP MF–3710) had been filed by the Procter & Gamble Co., 6100 Center Hill Rd., Cincinnati, OH 45224. The petition proposed to amend the GRAS regulations in 21 CFR part 582 to affirm that cellulose fines used as a feedstuff for livestock are GRAS.

Procter & Gamble Co. has now withdrawn the petition without prejudice to a future filing.

Dated: December 4, 1998.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 98–32812 Filed 12–9–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98P–0221]

Zeneca, Inc.; Withdrawal of Approval of Portion of a New Drug Application Providing for a Formulation of Diprivan Injectable Emulsion Not Containing Disodium Edetate

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of those portions of a new drug application (NDA) held by Zeneca, Inc., (Zeneca) for Diprivan (propofol) Injectable Emulsion that provide for a formulation not containing the antimicrobial additive disodium edetate.

EFFECTIVE DATE: December 10, 1998.

FOR FURTHER INFORMATION CONTACT: Virginia G. Beakes, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: By citizen petition dated April 7, 1998 (Docket No. 98P–0221/CP1), Zeneca, 1800 Concord Pike, Wilmington, DE 19850, requested that FDA withdraw approval of those portions of NDA 19–627 that provide for a formulation of Diprivan Injectable Emulsion that does not contain the antimicrobial additive disodium edetate, stating that the company discontinued marketing the product because of potential contamination problems observed after approval of the NDA. Zeneca waived its opportunity for a hearing.